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Inhibition of kinase IKKβ 
suppresses cellular abnormalities 
induced by the human 
papillomavirus oncoprotein HPV 
18E6
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Bing Zhang4, Ross L. Cagan5 & Lawrence Banks2
Human papillomavirus (HPV) is the leading cause of cervical cancer and has been implicated in several 
other cancer types including vaginal, vulvar, penile, and oropharyngeal cancers. Despite the recent 
availability of a vaccine, there are still over 310,000 deaths each year worldwide. Current treatments 
for HPV-mediated cancers show limited efficacy, and would benefit from improved understanding 
of disease mechanisms. Recently, we developed a Drosophila ‘HPV 18 E6’ model that displayed loss 
of cellular morphology and polarity, junctional disorganization, and degradation of the major E6 
target Magi; we further provided evidence that mechanisms underlying HPV E6-induced cellular 
abnormalities are conserved between humans and flies. Here, we report a functional genetic screen 
of the Drosophila kinome that identified IKKβ —a regulator of NF-κB—as an enhancer of E6-induced 
cellular defects. We demonstrate that inhibition of IKKβ reduces Magi degradation and that this 
effect correlates with hyperphosphorylation of E6. Further, the reduction in IKKβ suppressed the 
cellular transformation caused by the cooperative action of HPVE6 and the oncogenic Ras. Finally, we 
demonstrate that the interaction between IKKβ and E6 is conserved in human cells: inhibition of IKKβ 
blocked the growth of cervical cancer cells, suggesting that IKKβ may serve as a novel therapeutic 
target for HPV-mediated cancers.
Human papillomaviruses (HPV) are small, double-stranded circular DNA viruses that are obligate epithelio-
trophs: they specifically infect either squamous or mucocutaneous epithelia. The latter HPV types can be cat-
egorized into two classes: low-risk HPVs and high-risk HPVs. The former induce large and obvious benign 
lesions—condylomata—of the infected tissues. The latter are carcinogenic, causing most cervical cancers, as well 
as being strongly implicated in oropharyngeal, anal, vulvar, vaginal and penile  cancers1. Among all high-risk 
HPVs, HPV 16 and HPV 18 are the most prominent types, causing more than 70% of all invasive cervical can-
cers. According to World Health Organization (WHO), every year 570,000 women are diagnosed with cervical 
cancer, with a current mortality rate of more than 50%2,3.
The availability of effective vaccines against the most prevalent high-risk HPVs is expected to eventually 
reduce HPV-dependent tumors. However, the number of new HPV-induced cancer cases is not predicted to 
decline appreciably for the next few decades. Economic and cultural barriers hinder widespread immuniza-
tion in the middle- and low-income countries that account for the majority of cervical  cancers4. Furthermore, 
chronic HPV infection can require several decades to provoke  transformation5,6. Existing vaccines are only 
prophylactic against new HPV infections and are not effective against preexisting HPV infections, nor can they 
inhibit cancer progression and  malignancy7. As a result of these hurdles, effective treatment for HPV-induced 
cancer in general remains a major unmet clinical need. Current treatments for invasive HPV-induced cancers are 
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primarily radiation and chemotherapy, which show limited effectiveness and the survival rates of, for example, 
advanced-stage cervical cancer patients is  low8,9.
HPV 16 and HPV 18 direct cellular transformation through the persistent expression of two viral early genes, 
E6 and  E710,11. E6 and E7 oncoproteins cause cellular transformation through elimination of key tumor sup-
pressors P53, and Rb  respectively12–14. High-risk HPV E6s contain a PDZ binding motif (PBM) at the extreme 
C terminus that is absent in low-risk  E6s15. Interaction of the PBM with the PDZ domains of key host cellular 
PDZ domain proteins, including Magi, Dlg and Scribble, targets these proteins for ubiquitination and subsequent 
proteasome-mediated  destruction16–19. These PDZ domain-containing proteins are important components of 
tight junctions and cell polarity-controlling  complexes20–22. This action of E6 requires the assistance of the host 
E3 ubiquitin ligase, UBE3A and is necessary for cellular  transformation23,24. Transgenic mice expressing high-risk 
E6 and E7 in the skin develop cancers at high frequency; those expressing E7 and an E6 deficient in the PBM 
do not develop cancers. The failure to induce cellular transformation is independent of P53, as PBM-deleted E6 
retains the ability to inactivate  P5325. However, beyond the cellular targets of HPV oncogenes, we have a limited 
understanding of how persistent expression of E6 and E7 can lead to dysplasia and cancer.
Drosophila has proven a strongly useful platform for modeling human diseases including cancer, owing in part 
to high conservation of genes and signaling pathways, and the availability of a broad array of genetic  tools26–31. 
One particular advantage of Drosophila disease models is their use in functional genetic screens designed to 
discover novel targets and pathways that mediate human  disease32–34. In this study we used a recently developed 
Drosophila model of HPV18 E6 + UBE3A35 in a screen to identify kinases active in aspects of E6/UBE3A-induced 
transformation. We report that reduced activity of ‘inhibitor of nuclear factor kappa-B kinase subunit beta’ 
(IKKβ)—which regulates the innate immune response—strongly suppressed E6 + UBE3A-mediated cellular 
abnormalities, as well as rescuing degradation of E6 targets. We provide evidence that the IKKβ-mediated sup-
pression of Magi degradation is due to phosphorylation of E6, which was previously shown to block the interac-
tion of E6 with PDZ domain proteins. Further, reduction in IKKβ suppressed the cellular transformation caused 
by the cooperative action of HPVE6 and oncogenic Ras. Finally, we used a targeted inhibitor to demonstrate that 
reduced IKKβ activity results in strongly reduced growth of cultured human cervical cancer cells of established 
cell lines. Together, our results support the view that targeting IKKβ is a candidate strategy for developing novel 
lead therapeutics for HPV-induced cancer.
Material and methods
Fly strains. The following fly stocks were used: UAS-hUBE3A36, UAS-HPV18-E635, GMR-Gal4, Kinome set, 
IKKβ1/TM6B,Tb, UAS-IKKβ RNAi attp40, UAS-Ras64BV14 from Bloomington Drosophila stock center.
In vitro assays. To examine the effect of IMD 0354 on the growth of HaCat (HPV−ve), HeLa (HPV 18 +ve), 
CaSki and SiHa (both HPV 16 +ve), the cells were plated out and allowed to adhere overnight. Next day their cul-
ture medium was replaced and different concentrations of IMD 0354 (Santa Cruz Biotechnologies, Santa Cruz, 
CA) (final concentrations 250, 500, 750, 1000, 1250 nM, using DMSO to equalize input volumes and as negative 
control 0 nM) were added to the plates. Cells were counted 48 h later using a haemocytometer. The assay was 
repeated 3 times. One-way ANOVA test using the Prism program was used for statistical analysis.
Cell cycle and apoptosis analysis. HaCat, HeLa and CaSki cells were plated out at equal density, and 
allowed to attach overnight. The next day they were treated with 500 nM IMD354 (or DMSO alone) for 3 h, then 
harvested by typsinisation and centrifugation (the medium and all washes were also centrifuged to collect any 
floating or dead cells). The cell pellet was resuspended in citrate buffer with 0.1% NP-40, RNase and Propidium 
iodide, and incubated for 30 min in the dark at room temperature. FACS analyses were then performed (FAC-
Scalibur, Becton Dickinson) and the cell cycle profiles were analysed (10,000 events per run). The assays were 
performed four times. Analysis: the % of events recorded in the subG1 (Essentially apoptosis), G1, S and G2 
peaks for each run were compared between treated and untreated samples for each cell type and the fold change 
with treatment was calculated.
Western blot analysis. HPV18-positive HeLa cells were seeded on 6 cm dishes and allowed to attach over-
night. Fresh medium was then added, containing either 0, 100 nM or 500 nM IMD 0345 (in DMSO). After 5 h 
the cells were harvested in 2× SDS-PAGE gel loading buffer, run on SDS-PAGE, and analyzed by Western Blot. 
The membrane was probed with antibody specific for phosphorylated E6, as described  previously37,38. Following 
incubation with primary antibody, the appropriate horseradish peroxidase (HRP)-conjugated secondary anti-
bodies (Dako) were used, followed by enhanced chemiluminescence (ECL) detection according to the manufac-
turer’s instructions (GE Healthcare). Original blots provided in supplementary information.
Immunohistochemistry. For immunolabeling pupal eyes, 40–42 h after puparium formation, were dis-
sected in PBS and fixed in 4% formaldehyde. Fixed tissues were washed three times in PBS solution containing 
0.1% Triton-X-100 and blocked in 5% normal goat serum for 1 h before incubation with primary antibodies. 
The primary antibodies used in this study were rabbit anti-Magi 1:20039, rabbit anti-Baz 1:1000, rat anti-DE-cad-
herin 1:50 (Developmental Studies Hybridoma Bank). The appropriate secondary antibodies were conjugated 
Alexa488, Alexa594, and Alexa 647 (Invitrogen).
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Results
Kinome screen identified IKKβ as a mediator of E6 + hUBE3A-mediated defects. The fly eye is a 
compound eye consisting of 750 unit eyes. These ‘ommatidia’ are clusters of sensory neurons arranged in a pre-
cisely repeated hexagonal pattern formed by the precise arrangement of supporting pigment cells. Formation of 
this highly organized pattern requires precisely regulated cell proliferation, cell differentiation and programmed 
cell death; disruption of any of these processes leads to a disorganized, rough eye phenotype that is readily scored 
under a light  microscope40.
We have previously shown that co-expression of E6 and human UBE3A (hUBE3A) in the developing fly eye 
leads to a disorganized, rough eye phenotype. To identify loci that modify the E6 + hUBE3A-induced eye defects, 
we used mutations in the kinome to perform a dominant genetic modifier screen. Flies with stable integration 
of the transgenes GMR-Gal4, UAS-E6, and UAS-hUBE3A (referred to as GMR>E6/hUBE3A) were crossed to 
flies heterozygous for a mutant kinase. Comparing GMR>E6/hUBE3A; kinase+/− to GMR> E6/hUBE3A flies, we 
screened 195 kinases and identified IKKβ as the strongest suppressor of the E6 + hUBE3A-mediated rough eye 
Figure 1.  Reduction of IKKβ suppresses the E6 and UBE3A co-expression phenotypes. (A) Adult eye 
expressing GMR-Gal4 showing an intact eye morphology. (B) GMR-Gal4-driven co-expression of E6 and 
UBE3A causes rough eye morphology. (C) One mutated copy of IKKβ gene in GMR-Gal4 expressing eye has no 
effect on the eye morphology. (D) One mutated copy of IKKβ gene suppresses the E6 + UBE3A-induced rough 
eye defects. (E) Expression of IKKβ RNAi suppresses the E6 + UBE3A-induced rough eye defects.
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phenotype (Fig. 1D, compare with Fig. 1B; Fig. 1A,C are controls). Rescue was evident in 100% of flies (n = 40) 
with GMR>E6/hUBE3A; IKKβ+/− genotype and to the same extent shown in Fig. 1D. The rescue by reduced IKKβ 
activity was further confirmed with an RNA-interference transgene targeting IKKβ (Fig. 1E).
Inhibiting IKKβ in cervical cancer cells blocked their growth. IKKβ is a serine/threonine kinase that 
is highly conserved between flies and humans. It regulates the innate immune pathway by activating NF-κB, 
which in turn activates the expression of antimicrobial peptides to fight against  pathogens41–43. To determine 
whether IKKβ also has a functional link to E6 + UBE3A in human cells, we assessed the effect of the synthetic 
IKKβ inhibitor IMD 0354 (N-(3,5-Bis-trifluoromethylphenyl)-5-chloro-2-hydroxybenzamide)44 on the growth 
of HaCat (HPV−ve), HeLa (HPV 18 +ve), CasKi (HPV 16 +ve), and SiHa (HPV 16 +ve) cells. IMD 0354 is a 
non–adenosine triphosphate–binding (ATP-binding) competitive selective IKKβ inhibitor that prevents ATP 
attachment to IKKβ38. Different concentrations of the inhibitor were tested ranging from 250, 500, 750, 1000, 
to 1250 nM. IMD 0354 reduced growth of all four cell types; HeLa cells were most strongly affected, with a 
significant effect starting at the lowest concentration of 250 nM. While IMD 0354 had a significant effect on the 
HPV 18 and 16 positive cells, it had a minor effect on the growth of HaCat cells that lack HPV (Fig. 2A). This 
result suggested that the IKKβ-mediated mechanism of E6 + UBE3A-induced cellular abnormalities is conserved 
between humans and fruit flies. To understand whether the reduced cell number resulting from inhibition of 
IKKβ is due to arrest in cell cycle or to apoptosis, we treated these cells with 500 nM of IMD 0354 and analyzed 
their cell cycle profile 3 h post treatment. We found no increase in apoptotic cell death for HeLa and CaSki 
cells in comparison with HaCat cells. However, the majority of cells were found to exhibit a G1 cell cycle arrest 
(Fig. 2B,C). This finding indicated that the reduction in cell numbers upon IKKβ inhibition is due to a halt in cell 
growth and not to an increase in apoptotic cell death.
Reducing IKKβ suppressed the cellular defects caused by co-expression of E6 and hUBE3A. As 
reduction in IKKβ suppressed the rough eye phenotype caused by co-expression of E6 and hUBE3A, we exam-
ined the eye tissue of these flies 40 h after puparium formation, the time point at which the E6 + hUBE3A effect 
becomes apparent. In the normal pupal eye, each ommatidium consists of eight photoreceptor cells covered by 
four glial-like cells or cone cells and two primary pigment cells. Neighboring ommatidia are separated from each 
other by a lattice of secondary and tertiary pigment cells and the sensory bristle cells. This interweaving lattice of 
pigment cells organizes the ommatidial array into a precise pattern of repeated  hexagons45.
Pupal eyes expressing E6 and hUBE3A exhibit severe morphological defects, including fusion of neighboring 
ommatidia, increase in the number of pigment cells and cone cells, and a severe alteration in the stereotyped 
pattern of ommatidia. In comparison, removing a single genomic copy of IKKβ (GMR>E6/hUBE3A; IKKβ+/−) 
led to a strong phenotypic rescue: pigment and cone cell defects were reduced and the overall organization of the 
ommatidial array improved (Fig. 3A–C). These observations suggest that E6 interferes with a molecular mecha-
nism involving IKKβ and that this mechanism plays an important role in E6-induced cellular abnormalities.
Reducing IKKβ suppressed the junctional and polarity defects caused by co-expression of E6 
and hUBE3A. We have previously shown that E6, in cooperation with UBE3A, perturbs the integrity of 
junctional and polarity  complexes35. Therefore, we hypothesized that reducing IKKβ activity might suppress 
these defects. Immunolabeling for junctional marker E-cadherin and polarity marker Bazooka (the homolog 
of human Par-3) revealed that, in comparison with pupal eyes expressing E6 and UBE3A, in which both the 
junctional and polarity complexes were perturbed in ommatidia (Fig.  3 E–H′), GMR>E6/hUBE3A; IKKβ+/− 
pupal eyes showed no disruption of junctional and polarity complexes and the integrity of these complexes was 
restored to the extent seen in control eye tissues (Fig. 3F–I′ compared to D–G′). These observations suggest that 
alterations in IKKβ significantly contribute to the E6-induced cellular junctional and polarity disorganization.
Reduced IKKβ activity suppressed E6 + hUBEA-induced degradation of PDZ domain pro-
teins. Proteasomal degradation of PDZ domain-containing proteins, including Magi, Dlg, and Scribble, was 
shown to be crucial for the cancerous effect of HPV 16 and 18  E625. We have previously shown that HPV 18 E6, 
with the addition of human UBE3A, targets the fly counterparts of these proteins for ubiquitin-mediated protea-
somal  destruction35. As a reduction in IKKβ levels suppressed the cellular defects caused by E6 plus hUBE3A, 
we asked whether the E6-mediated degradation of PDZ domain proteins was altered. To address this ques-
tion we examined the level of Magi, as Magi has been identified as a major degradation target of HPV18 E6 in 
human and Drosophila19,35. Immunolabeling of pupal eyes for Magi revealed that, whereas GMR>E6/hUBE3A 
eyes exhibited a complete loss of Magi, GMR>E6/hUBE3A; IKKβ+/− pupal eyes exhibited no detectable loss of 
Magi (Fig. 4A–C). This result suggests that reducing IKKβ activity suppresses the E6-induced degradation of 
Magi, and that rescue of Magi degradation is likely to play a role in suppression of E6-induced cellular defects.
Reducing IKKβ resulted in hyperphosphorylation of E6. Phosphorylation of the HPV 18 E6 PBM 
was previously demonstrated to block its interaction with PDZ domain proteins Dlg and  Magi37,46,47. To assess 
whether phosphorylation-mediated regulation of E6 plays a role in suppressing Magi degradation, we treated 
cells expressing HPV 18 E6 with the IKKβ inhibitor IMD 0354 (at 100 and 500 nM) and compared with untreated 
cells for E6 phosphorylation. Western blot analysis was performed using an antibody to detect phosphorylated 
E6. We found that inhibition of IKKβ resulted in extensive phosphorylation of E6, which was absent in untreated 
cells (Fig. 4D). This result is consistent with previous findings, and suggests that the lack of Magi degradation in 
cells expressing E6 + hUBE3A with mutated IKKβ could be due to the loss of PDZ recognition by E6.
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Figure 2.  Inhibition of Human IKKβ in cervical cancer cells blocks their growth. (A) Five different concentrations (250, 500, 750, 
1000, 1250 nM) of human IKKβ inhibitor, IMD 0354, were applied to HPV-negative (HaCat), HPV 18-positive (HeLa), and HPV 
16-positive (CaSki and SiHa) cells and the effect was measured by number of surviving cells after 48 h. The inhibitor blocks the growth 
of HPV 16 and 18 cervical cancer cells without a significant effect on the HaCat cells, showing a most significant effect on HeLa cells: 
reducing the initial number of cells to 40%, at starting concentration of 250 nM and 10% at 1250 nM. Data are presented as mean ± SD 
(n  =  3); not significance (n.s.) = P  >  0.05; *P  <  0.05, **P  <  0.01. One-way ANOVA test using the Prism program was used for 
statistical analysis. (B) HPV-negative (HaCat), HPV 18-positive (HeLa), and HPV 16-positive (CaSki) cells were treated with 500 nM 
of human IKKβ inhibitor, IMD 0354, or with DMSO as control. After 3 h cells were trypsinized and stained with Propidium Iodide, 
and the cell cycle profiles were analysed by FACS. n =  4. Representative cell cycle profiles are shown for each cell type and condition. 
(C) The cell cycle FACS profiles were analysed to determine the number of cells in subG1 (i.e. apoptotic), G1, S and G2M phases of 
the cell cycle. The histogram shows the results from four experiments expressed as the fold change in cell number upon IMD 0354 
treatment, relative to DMSO treatment. Standard deviations are shown. The assay was repeated 4 times, n = 4.
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Reducing IKKβ suppressed the cooperative effect of Ras and E6 + hUBE3A. Previous studies 
have shown that the HPV oncogenes E6 and E7 alone are insufficient to direct oncogenic transformation, and 
that other factors including genetic alterations contribute to HPV-induced tumorigenesis in humans and  mice48. 
Mutations in Ras family proteins have been implicated in HPV-related cancers, and we have previously shown 
that cooperation between E6 and oncogenic isoforms of Drosophila Ras  (Ras64BV14) promotes cellular transfor-
mation and malignancy in fly  epithelia35,48–50. Therefore, we asked whether reducing IKKβ activity can suppress 
Figure 3.  Reduction of IKKβ suppresses the cellular abnormalities and restores the cell polarity and junctional 
integrity disrupted by E6 + UBE3A co-expression. (A–C) Pupal eyes showing E-Cad immunolabeling. (A) 
Expression of GMR-Gal4, showing a normal stereotype pattern of ommatidia. (B) Co-expression of E6 and 
UBE3A causes severe abnormalities, including increase in number of pigment cells, bristle cells, and fusion 
of neighboring ommatidia. (C) A mutated copy of the IKKβ gene suppresses the E6 + UBE3A abnormalities. 
(E–H′) Co-expression of E6 and UBE3A causes disruption of cell polarity and junctional complex, as shown 
by loss of Bazooka (Baz) and E-Cad from photoreceptor cells. This is in comparison with (D–G′) where Baz 
and E-Cad are both localized correctly in each photoreceptor. (F–I′) A mutated copy of IKKβ gene in eyes 
expressing E6 and UBE3A restores the polarity and junctional integrity as is shown by the correct localization of 
Baz and E-Cad. Scale bars indicate 10 µm. Insets are digitally magnified 200%. Results shown are representative 
of those of 5 different flies.
7
Vol.:(0123456789)
Scientific Reports |         (2021) 11:1111  | https://doi.org/10.1038/s41598-020-80193-5
www.nature.com/scientificreports/
the cellular transformation caused by the cooperation of oncogenic Ras and E6. Co-expression of oncogenic 
Ras,  Ras64BV14 with E6, and hUB3A in eye imaginal discs (GMR>E6/hUBE3A/Ras64BV14) at 25 °C resulted in 
overgrowth and pupal lethality (Fig. 5A). However, when the level of IKKβ was reduced (GMR>E6/hUBE3A/
Ras64BV14; IKKβ+/−), the lethality was rescued and flies developed to adulthood. These adult flies, however, still 
exhibited significant abnormalities in eye morphology, suggesting incomplete rescue (Fig. 5B).
Gal4 activity is reduced at lower  temperatures51. At 22 °C, GMR>E6/hUBE3A/Ras64BV14 flies developed to 
adulthood, exhibiting enhanced transformed eye morphology in comparison to expression of oncogenic Ras 
alone (Fig. 5D compared to 5C). Reducing IKKβ activity significantly suppressed the transformed eye morphol-
ogy in these conditions (Fig. 5E), further demonstrating that IKKβ is important for the cooperative action of 
E6 and oncogenic Ras.
Discussion
In this study we identify IKKβ as a mediator of the HPV 18 E6 and hUBE3A-induced cellular defects in both fly 
and human cancer models. This is consistent with previous studies demonstrating that HPV 16 E6 interacts with 
components of the innate immune pathway, including IKKβ, and it activates the NF-κB transcription  factor52,53. 
The role of the innate immune system in HPV infection and cancer progression is not well understood. Activation 
of the innate immune system, particularly the Toll pathway, has been associated with regression and clearance 
of HPV 16  infection54. This is consistent with other studies demonstrating that HPV 16 oncogenes repress the 
expression of a key innate immune sensor, Toll like receptor 9 (TLR9)55, suggesting that persistent infection may 
reflect a defect in the host innate immune system. Conversely, activation of the innate immune system, and con-
sequent inflammation, contributes to HPV-induced tumor  progression56. Several studies have shown an increase 
in the level of inflammatory cytokines in individuals with reduced HPV  clearance57–59. Additionally, upregulation 
of several TLRs and components of the NF-κB signaling pathway have been implicated in HPV-related cancers. 
It has been suggested that the malignant phenotype of cervical cancer cells requires the function and activation 
of IKKβ/NF-κB  signaling60,61. IKKβ phosphorylates the inhibitor of NF-κB, resulting in its ubiquitination and 
Figure 4.  Reduced activity of IKKβ causes hyperphosphorylation of E6 and suppression of E6 + UBE3A-
mediated degradation of PDZ domain protein, Magi. (A–C) Pupal eyes showing Magi immunolabeling. (B) 
Co-expression of E6 + UBE3A results in loss of Magi from cone cells and pigment cells compared with (A) in 
which only the Gal4 driver is expressed. (C) A mutated copy of the IKKβ gene suppresses the E6 + UBE3A-
mediated loss of Magi. (D) Western blot of HeLa cell extracts shows that inhibition of IKKβ using a 
concentration of 500 nM of the inhibitor IMD 0354 results in phosphorylation of E6; compare that to lack of E6 
phosphorylation in HeLa cells grown with no inhibitor (untreated) or with a low concentration of 100 nM. Scale 
bar indicates 10 µm. Results shown in (A–C) are representative of those of 5 different flies. Result shown in (D) 
is a representative of n = 3.
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proteasomal degradation. This action of IKKβ frees the NF-κB, which in turn enters the nucleus and activates 
the transcription of pro-inflammatory, pro-cell proliferation and anti-apoptotic  genes62,63. Increased expression 
of IKKβ and its association with an aggressive phenotype has been reported in several types of cancers including 
head-and-neck, ovarian and liver  cancers64–66. It is notable that IKKβ’s role in cancer is not only limited to its 
function in regulation of the NF-κB pathway; IKKβ can also phosphorylate p53, resulting in its ubiquitination 
and subsequent degradation. Inactivation or loss of p53 has been identified in more than 50% of cancers, includ-
ing HPV-induced cancers: high-risk HPV E6s target p53 for ubiquitination and proteasomal  degradation14,67. 
IKKβ-mediated loss of p53 can be suppressed by inhibition of IKKβ in cancer  cells68,69. The inhibitory function 
of IKKβ on p53 was further found in HPV38E6E7 human keratinocytes. IKKβ phosphorylates and stabilizes a 
dominant-negative inhibitor of p53, ∆Np73α, resulting in repression of p53-regulated genes such as p21. This 
inhibitory effect of IKKβ on p53 can be suppressed upon its inactivation, which results in destabilization and 
degradation of ∆Np73α70. Another phosphorylation target of IKKβ is fork-head transcription factor FOXO3a. 
IKKβ has been found to stimulate cell cycle progression and proliferation of breast cancer cells, through phos-
phorylation of FOXO3a, leading to its exclusion from nucleus and subsequent degradation in the proteasome. 
This function of IKKβ could be further overridden by the overexpression of  FOXO3a71. All these findings sug-
gest that IKKβ may contribute to HPV-induced cellular abnormalities in several ways, some through the innate 
immune pathway, and some independent of it.
IKKβ inhibitors have served as potent anti-tumor agents inhibiting cell proliferation and invasiveness, as 
well as inducing cell death. Their activity has been demonstrated in several cancer types including breast, colon, 
ovarian, oral, prostate, liver, melanoma, and  leukemia65,66,72–76. One such inhibitor is IMD 0354, which selec-
tively inhibits IKKβ by preventing ATP attachment to IKKβ. This will in turn block phosphorylation of IκBα, 
thus preventing nuclear translocation and activation of NF-κB38. Although IMD 0354 was initially designed to 
inhibit  inflammation77, it has recently proved to have strong anticancer  properties78,79 in several cancers. IMD 
0354 inhibits breast cancer cell proliferation, progression of mast cells, and it induces apoptosis in prostate, lung 
and colon  cancers44,80–82. In our study we found that IMD 0354 inhibited the growth of HPV 16+ and 18+ cer-
vical cancer cell lines. This result is consistent with previously reported function of IMD 0354 in cancer cells 
and hence suggests a therapeutic potential for IKKβ inhibitors to treat HPV-induced cancers. Although both 
HPV16+ and HPV18+ cervical cancer cell lines responded to IMD 0354, however, IMD 0354-mediated inhibi-
tion of IKKβ exhibited greater effectiveness on HeLa cells (HPV 18+) compared with SiHa and CaSki cells (HPV 
16+). It has previously been demonstrated that these cell lines differ in a number of molecular pathways, and 
in their response to treatments such as therapeutic agents that induce cell  death83–85. HeLa cells exhibit greater 
apoptotic cell death in response to cisplatin than SiHa and CaSki cells do, a difference that is due to the higher 
levels of p53 and p21 in HeLa  cells84. Additionally, these cell lines show distinct proteomic profiles for pathways 
connected to p53 activation, mitochondrial function and oxidative  stress85,86. These findings suggest that the 
stronger effect of IMD 0354 in HeLa relative to SiHa and CaSki cells could in part be due to their difference 
Figure 5.  Reduction of IKKβ suppresses the cellular transformation caused by cooperative action of Ras 
and E6 + UBE3A. (A,B) Expression of transgenes at 25 °C. (B) A mutated copy of IKKβ gene in eyes expressing 
E6, UBE3A and an oncogenic Ras, suppresses pupal lethality and the severe defects caused by cooperative action 
of E6, UBE3A and oncogenic Ras (A). (C–E) Expression of transgenes at 22 °C. (C) Expression of oncogenic Ras 
in the eye causes cellular transformation. (D) Co-expression of E6 and UBE3A with oncogenic Ras enhances 
the Ras phenotype. (E) A mutated copy of IKKβ gene suppresses the severe eye abnormalities mediated by the 
synergistic effect of oncogenic Ras, E6 and UBE3A. Results shown are representative of those of 5 different flies.
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in molecular pathways affected by IKKβ. Additionally, IMD 0354 caused an extensive phosphorylation of E6, 
which was absent in untreated cells. This finding is intriguing, as phosphorylation of E6 on the PDZ binding 
motif results in disruption of its interaction with PDZ domain-containing  proteins46,47. This is consistent with 
our results, as degradation of Magi was inhibited when IKKβ was reduced. It would be of interest to understand 
the mechanism by which inhibition of IKKβ results in E6 hyperphosphorylation.
In summary this study suggests an important role for IKKβ in E6-induced cellular abnormalities and that 
targeting IKKβ could be a potential therapeutic option for cervical cancer and, perhaps, for other HPV-related 
cancers for which there is currently no effective treatment.
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